Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

146 results about "Squamous carcinoma" patented technology

Squamous cell carcinoma is an extremely common form of skin cancer which is usually benign, especially if caught early. In almost 97% of cases, the cancer can be excised and the patient will fully recover. ... The first sign of squamous cell carcinoma is usually a reddened, scaly patch on the skin. Sometimes a lump or nodule will develop.

Esophageal squamous carcinoma detection method and system based on combination of multi-modal information fusion and artificial intelligence

The invention provides an esophageal squamous carcinoma detection method and system based on combination of multi-modal information fusion and artificial intelligence, and relates to the technical field of detection. And inputting the fusion feature map corresponding to the multi-modal image information into a pre-trained esophageal squamous carcinoma detection model to perform focus area detection and segmentation on the fusion feature map, and based on a detection result, performing benign and malignant classification and staging prediction on a detected focus by using an integrated learning method in combination with a classification algorithm to obtain the esophageal squamous carcinoma. Outputting a classification result and a visual heat map; converting the extracted focus area information into three-dimensional point cloud data by using an improved point cloud reconstruction algorithm; performing space division and noise reduction processing on the three-dimensional point cloud data by adopting a self-adaptive octree structure; and generating a smooth lesion three-dimensional model by using an improved Poisson surface reconstruction algorithm in combination with a curved surface subdivision technology.
Owner:THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV

Application of tageteoside in resisting esophageal squamous cell carcinoma

ActiveCN119074752Asure easyOrganic active ingredientsDigestive systemFructosediphosphate AldolaseTyrosine
The invention provides application of tageteoside in resisting esophageal squamous cell carcinoma. The invention finds that tyrosine 174, 302, 328 sites of fructose diphosphate aldolase (ALDOA) are highly expressed in esophageal squamous cell carcinoma tissues and are in negative correlation with prognosis of esophageal squamous cell carcinoma patients; the tageteoside can play a role in resisting esophageal squamous carcinoma, and can inhibit activation of phosphorylation sites of ALDOA tyrosine 174, 302 and 328 in esophageal squamous carcinoma cells in a dose-dependent manner. Therefore, the tageteoside is an effective medicine for resisting esophageal squamous carcinoma.
Owner:BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL

Early esophageal squamous carcinoma detection method and system based on deep learning

The invention provides an early-stage esophageal squamous carcinoma detection method and system based on deep learning, and relates to the technical field of image processing, and the method comprises the steps: obtaining an esophageal endoscope image, carrying out the enhancement processing, carrying out the multi-stage decomposition, generating a first image, carrying out the background separation of the first image, generating a region of interest, and carrying out the morphological filtering and edge extraction; generating a binary mask image and performing normalization processing to obtain a standard image; extracting semantic features of the standard image, performing pixel-level classification on the semantic features to obtain a region segmentation result, calculating morphological features and textural features of an esophageal squamous cell carcinoma region, performing classification to obtain an esophageal squamous cell carcinoma classification result, adding the esophageal squamous cell carcinoma classification result as an input feature into a first classification model, and judging esophageal tissues according to a judgment standard to obtain an esophageal squamous cell carcinoma classification result; generating a first judgment result, performing nonlinear mapping and classification to obtain a second judgment result, and performing fine segmentation to obtain an accurate boundary of the early esophageal squamous carcinoma tissue.
Owner:THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV

SHAP interpretability-based lung squamous cell carcinoma survival prediction method and system

The invention discloses a lung squamous cell carcinoma survival prediction method and system based on SHAP interpretability, and relates to the technical field of medical data analysis. Comprising the following steps: constructing a dynamically updated physiological feature information table based on a lung squamous cell carcinoma clinical data set of a target under multiple time nodes; and associating different survival analysis models with the physiological feature information table to predict the survival probability of the lung squamous cell carcinoma in the target body, the marginal contribution of each input feature to the output of each model is obtained by using the SHAP interpretation algorithm, and the feature uniqueness score is transparently displayed in the fusion process, so that the survival probability of the lung squamous cell carcinoma in the target body can be predicted in the actual use process. The method can visually understand how each feature affects the final prediction, and achieves automatic arbitration or manual recheck through providing a model to explain conflict measurement, invalid variable elimination and pseudo high risk verification and weighted scoring, thereby guaranteeing the reasonability and safety of prediction and intervention suggestions, reducing the decision risk, and enhancing the clinical trust.
Owner:PEKING UNIVERSITY THIRD HOSPITAL (THE THIRD CLINICAL MEDICAL SCHOOL OF PEKING UNIVERSITY)

Tumor vaccine and application thereof

The present disclosure relates to a tumor vaccine for treatment of esophageal squamous carcinoma and other cancers and a composition thereof, and specifically discloses a polypeptide comprising one or more antigen fragments selected from the group consisting of ACTL8, BRDT, FOXI3, GNGT1, SMC1B, PLAC1, MAGEA1, MAGEA3, MAGEA4, MAGEA6, MAGEA10 and MAGEA11, the one or more antigen fragments are connected by a linker peptide, and the antigen fragment comprises one or more antigen epitope peptides. In addition, the disclosure provides a linear epitope peptide, a nucleic acid encoding the polypeptide and the linear epitope peptide, and a use of the polypeptide or the linear epitope peptide in the preparation of a medicament for preventing or treating cancers such as esophageal squamous carcinoma.
Owner:BEIJING IMMUPEUTICS MEDICINE TECH LTD

Application of luteoloside-sensitized cis-platinum in preparation of esophageal squamous cell carcinoma treatment medicine

The invention relates to an application of galuteolin-sensitized cis-platinum in preparation of a medicine for treating esophageal squamous cell carcinoma. It is found that the galuteolin can block the progress of esophageal squamous carcinoma cells in multiple links including apoptosis induction, growth and invasion inhibition and the like, the galuteolin can also significantly enhance inhibition of cis-platinum on lymphatic metastasis of esophageal squamous carcinoma cells in a mouse model, and the galuteolin and the cis-platinum have a significant synergistic effect.
Owner:BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL

Disturbance response scanning analysis-based lung squamous cell carcinoma drug discovery method and system

The invention discloses a lung squamous cell carcinoma drug discovery method and system based on disturbance response scanning analysis, and belongs to the field of biological medicines.The method comprises the steps that lung squamous cell carcinoma protein expression profile data is downloaded and preprocessed, a robust network module is constructed and multi-scale analysis and evaluation are conducted, and drug genomic data are obtained based on drug genomic data. Predicting the drug sensitivity of the patient by using machine learning, and generating a DRN through difference analysis of the drug sensitivity; predicting drug-target protein binding affinity in combination with deep learning, quantifying node sensitivity through a PRS technology, calculating a DPI disturbance score and ranking drug priorities; high-ranking drugs are screened through comprehensive sensitivity analysis and literature investigation; a drug for a lung squamous carcinoma cell line is screened out through a pre-experiment and is relocated. According to the framework developed by the invention, by integrating proteomics, pharmacogenomics and dynamic network analysis, systematic analysis is provided for relocation drug identification of lung squamous cell carcinoma, and good news is brought to treatment of lung squamous cell carcinoma.
Owner:SUZHOU UNIV

Application of chrysin-sensitized cis-platinum in treatment of esophageal squamous cell carcinoma

The invention relates to application of chrysin-sensitized cis-platinum in treatment of esophageal squamous cell carcinoma. It is found that chrysin can sensitize the growth inhibition effect, invasion inhibition effect and apoptosis induction effect of cis-platinum-mediated esophageal squamous carcinoma cells in a dose-dependent manner, and can effectively enhance the growth inhibition and apoptosis promotion effect of cis-platinum-mediated tumors to inhibit the increase of the tumor volume. The inhibition of cis-platinum on lymphatic metastasis of esophageal squamous carcinoma cells is remarkably enhanced, and a synergistic anti-cancer effect is generated through combination of cis-platinum and cis-platinum.
Owner:BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL

Application of fatty acid oxidation inhibitor in improving cis-platinum resistance of esophageal squamous carcinoma

The invention discloses an application of a fatty acid oxidation inhibitor in improving cis-platinum resistance of esophageal squamous carcinoma, and particularly relates to the technical field of biology. The invention discloses application of a fatty acid oxidation inhibitor in preparation of a product for improving cisplatin resistance of esophageal squamous carcinoma. The fatty acid oxidation inhibitor is etomox. The invention discloses a very good effect of the fatty acid beta oxidation inhibitor Etomoxir on weakening the cisplatin resistance of esophageal squamous carcinoma cells induced by M2 type macrophage-derived GDF15 for the first time. According to the invention, the fatty acid beta oxidation inhibitor Etomoxir is combined with cis-platinum to be applied to the treatment process of esophageal cancer, so that the esophageal cancer chemotherapy drug resistance process mediated by tumor-associated macrophages is effectively weakened.
Owner:SHIHEZI UNIVERSITY

Application of chrysin-sensitized VS4718 or ponatinib in treatment of esophageal squamous cell carcinoma

The invention provides an application of chrysin-sensitized VS4718 or ponatinib in treatment of esophageal squamous cell carcinoma. It is found that chrysin can sensitize the growth inhibition effect and the invasion inhibition effect of esophageal squamous carcinoma cells mediated by VS4718 or ponatinib and can effectively enhance the tumor metabolism inhibition mediated by VS4718 or ponatinib, and the chrysin is combined with VS4718 or ponatinib to generate the synergistic anti-cancer effect.
Owner:BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL

CKS1B as immunotherapy response prediction biomarker and application thereof

The invention belongs to the technical field of biological medicine, and provides CKS1B serving as an immunotherapy response prediction biomarker and application of the CKS1B, and according to the application, CKS1B serves as an immunotherapy response marker, and a CKS1B inhibitor is combined with an active component to treat a model mouse. In-vitro cell experiments are adopted to evaluate the immunotherapy prediction effect of the CKS1B as a biomarker on esophageal squamous carcinoma, a Cks1b overexpression tumor mouse model, a homologous mouse model and a human immune reconstruction mouse model are established, and a CKS1B inhibitor is combined with active ingredients to treat the two models; results show that the CKS1B inhibitor combined with the active component can promote removal of esophageal squamous carcinoma cells by CD8 + T cells, inhibit interferon signal channels and antigen presentation, effectively recover immune response, inhibit tumor cell proliferation and significantly reduce tumor volume, so as to achieve the purpose of treating esophageal squamous carcinoma.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI

Head and neck squamous cell carcinoma early recognition method based on radiomics and deep learning

The invention relates to the technical field of medical image processing and intelligent grading recognition of tumors, and discloses a head and neck squamous cell carcinoma early recognition method based on radiomics and deep learning, which comprises the following steps: acquiring head and neck CT (Computed Tomography), MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) three-mode image data; a two-stage dynamic structure alignment mechanism is adopted for registration; extracting fusion radiomics features; constructing a tumor sub-feature map; outputting a tumor level and a prediction confidence coefficient through the uncertainty prediction model; and generating a saliency interpretation heat map. In the prior art, a single-mode image or a superficial layer texture feature extraction model is depended on, and especially under the condition that a heterogeneity tumor region boundary is fuzzy and different modes have significant structure offset, high-confidence accurate discrimination of a real staging state of a tumor cannot be realized. According to the method, the accuracy of early stage identification of the head and neck squamous cell carcinoma is improved by introducing the significance guide registration mechanism and the improved graph convolutional neural network and combining Dropout reasoning.
Owner:THE SIXTH MEDICAL CENT OF THE CHINESE PEOPLES LIBERATION ARMY GENERAL HOSPITAL

FomA-targeted mRNA vaccine and application thereof in immunotherapy of esophageal squamous carcinoma

The invention relates to an mRNA (messenger Ribonucleic Acid) vaccine targeting FomA and application of the mRNA vaccine in immunotherapy of esophageal squamous carcinoma in the technical field of tumor immunotherapy. The problems that in the prior art, a specific targeting vaccine for the fusobacterium nucleatum membrane protein FomA lacks, traditional antibiotics can only kill extracellular bacteria and cannot remove intracellular colonized fusobacterium nucleatum, and cellular immunity cannot be effectively activated to remove fusobacterium nucleatum colonized in tumor tissue; the immunotherapy drug resistance of esophageal squamous carcinoma caused by fusobacterium nucleatum infection is difficult to reverse. According to the technical scheme, an mRNA molecule with a fusobacterium nucleatum FomA extracellular domain tandem repeat sequence and a lipid nanoparticle delivery system are coded, an extramembrane segment tandem repeat immune enhancement technology is adopted for design, two extracellular ring sequences are repeated for 2-5 times and connected through a connector sequence, lipid nanoparticles are composed of optimized quaternary lipids, and the lipid nanoparticles are prepared from the quaternary lipids. And a PD-1 monoclonal antibody is combined to activate FomA specific CD8 + T cell immunoreaction, so that comprehensive removal of intracellular and extracellular bacteria and bacteria targeted immune remodeling are realized.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Esophageal squamous carcinoma risk prediction model training method, esophageal squamous carcinoma risk prediction method and esophageal squamous carcinoma risk prediction system

The embodiment of the invention provides a training method of an esophageal squamous carcinoma risk prediction model, and an esophageal squamous carcinoma risk prediction method and system, and belongs to the technical field of medical treatment. According to the scheme, a training feature set is obtained, global importance analysis is carried out on the training feature set through a plurality of different feature selection algorithms, and an importance scoring result of each feature selection algorithm and consensus feature results of all the feature selection algorithms are obtained; performing screening processing according to each importance scoring result to obtain a feature subset corresponding to each feature selection algorithm; inputting each feature subset into a plurality of different classifier algorithms for training to obtain a corresponding basic model; a plurality of high-performance models are screened out from all the basic models through a multi-criterion decision classification fusion framework for weighted fusion, input features after model fusion are determined according to consensus feature results, an esophageal squamous cell carcinoma risk prediction model is obtained, the accuracy of esophageal squamous cell carcinoma risk prediction can be improved, and potential patients can be found in advance.
Owner:SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)

Mouse esophageal squamous carcinoma cell line and application thereof

PendingCN118995615AFind and optimize treatment modalitiesCompound screeningApoptosis detectionEsophageal cancerClinical research
The invention belongs to the field of biological medicine, and relates to a mouse esophageal squamous carcinoma cell line and application thereof. The esophageal cancer cell line is named as SYEC2 and is preserved in Guangdong Microbial Culture Collection Center, and the preservation number is GDMCC NO.64654. The esophageal cancer cell line is named as SYEC2. The esophageal cancer cell line conforming to clinical research and the organ-like model and the animal model prepared from the esophageal cancer cell line are obtained, and the model can provide a favorable tool in the research fields of researching the occurrence and development mechanism of esophageal cancer, searching and optimizing new possible treatment modes of esophageal cancer and the like.
Owner:SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)

A partitioned delivery environment-responsive hydrogel microneedle, a preparation method thereof and application thereof in oral squamous carcinoma treatment

PendingCN122624360AMouth mucosaOral Microflora
The application discloses a kind of partition delivery environment response type hydrogel microneedle and its preparation method and application in oral squamous carcinoma treatment.The hydrogel microneedle includes backing layer and the needle tip layer being arranged on the surface of the backing layer, the needle tip layer includes multiple array distribution microneedle tip body, each the needle tip body is connected with the backing layer respectively;Wherein, the backing layer has enzyme response, and the needle tip layer has acidic pH response.The microneedle uses innovative "integration partition design", and two hydrogels with different functions are integrated in single microneedle array: backing layer responds oral flora imbalance microenvironment, needle tip layer responds tumor weak acidic microenvironment.The design can realize partition, accurate, intelligentized synergistic treatment to oral mucosa surface and deep tumor tissue, so as to overcome the technical bottleneck of traditional dosage form in space selectivity, single drug type, release behavior uncontrollable and great systemic toxicity etc.
Owner:SUN YAT SEN UNIV

Biomarker for accurate typing of esophageal squamous carcinoma lesion and application of biomarker

The invention discloses a biomarker for accurate typing of esophageal squamous carcinoma lesion and application of the biomarker, and belongs to the technical field of molecular biology, the biomarker is SOX2 protein and KDM4B protein which are co-localized in nuclei, and the biomarker is applied to accurate typing of esophageal squamous carcinoma lesion with a non-diagnostic purpose. The cell proportion and distribution conditions of the SOX2 protein and the KDM4B protein are simultaneously displayed on the same section by adopting a double-label immunofluorescence method, and tests prove that the intranuclear co-localization of the SOX2 and the KDM4B can be used as an early warning mark and is used for identifying high-risk patients or early stages of precancerous lesions or distinguishing tumor patients, so that the missed diagnosis rate is reduced, and the diagnosis time is shortened. Therefore, a reliable basis is provided for accurate typing of esophageal squamous carcinoma lesions.
Owner:SICHUAN CANCER HOSPITAL

Polypeptide in targeted combination with SOX2 protein and application thereof

The invention relates to the technical field of biological medicine, and relates to a polypeptide in targeted combination with SOX2 protein and application thereof, the polypeptide has an amino acid sequence as shown in SEQ ID NO.1, or has at least 85%, 90%, 95% or more than 99% of sequence identity with the amino acid sequence; the polypeptide inhibits phase separation of SOX2, liquid drops formed by phase separation of SOX2 can be avoided, then the situation that the liquid drops wrap chemotherapeutic drugs, influence the curative effect of the chemotherapeutic drugs and cause tolerance of tumor cells to the chemotherapeutic drugs is avoided, and the polypeptide does not influence the transcription activation function of SOX2 serving as a transcription factor; the polypeptide can inhibit the phase separation of the SOX2, so that the regulation of normal physiological functions, such as high expression in organs such as eyes of a human body, of the SOX2 as a transcription factor is not influenced, and therefore, the polypeptide disclosed by the invention can reverse chemotherapy drug resistance of tumors such as squamous carcinoma by inhibiting the phase separation of the SOX2, can be used for adjuvant therapy of the tumors such as squamous carcinoma, and has no obvious toxic or side effect on each organ of an organism.
Owner:GUANGZHOU NAT LAB

Application of ginkgetin in enhancing VS4718 or ponatinib in resisting esophageal squamous cell carcinoma progress

The invention provides an application of ginkgetin in enhancing VS4718 or ponatinib in resisting the progress of esophageal squamous cell carcinoma. It is found that ginkgo biflavone can enhance the growth and invasion inhibition effect of VS4718 or ponatinib on esophageal squamous carcinoma cells; ginkgo biflavone is used for enhancing the inhibition effect of VS4718 or ponatinib on glycolipid metabolism of tumor cells, and the ginkgo biflavone is respectively combined with VS4718 or ponatinib to generate a synergistic anti-cancer effect.
Owner:BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL

Novel fusobacterium strain Fusobacterium sp.HPSCC05 and application thereof

The invention discloses a novel fusobacterium strain Fusobacteria sp.HPSCC05 and an application of the novel fusobacterium strain Fusobacteria sp.HPSCC05. The preservation number of the novel fusobacterium strain Fusobacteria sp.HPSCC05 is CCTCC (China Center For Type Culture Collection) NO: M2025588. According to the invention, Fusobacterium sp.HPSCC05 derived from hypopharyngeal squamous cell carcinoma tissues is successfully separated, the strain has key technical attributes of stable growth, repeatable culture, clear preservation conditions and the like, and the problem of deficiency of current hypopharyngeal carcinoma related strains is solved. Fusobacteria sp.HPSCC05 is identified as a new fusobacterium species, and the blank of hypopharyngeal carcinoma tumor ecological niche specific strain resources is filled up. The method comprises the following steps: establishing an in-vitro verification model (fusobacterium-hypopharyngeal squamous carcinoma cell co-culture model) of the hypopharyngeal carcinoma promoting effect of the Fusobacterium sp.HPSCC05, and providing a replicable culture mode;
Owner:EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV

Nucleic acid aptamer for detecting paclitaxel-resistant esophageal cancer

The invention discloses a nucleic acid aptamer for detecting paclitaxel-resistant esophageal cancer, which is a section of nucleotide sequence with the length of 80bp, and the sequence of the nucleotide sequence is as follows (5 '-3'): V1: CTTCCAGCAGACC TCACGGGGAGAAGCAGGGGGTATGGACCTTCGGTTATAACGACGGTGTATGATGAGCG; or V5: CTTCCAGCCAGACCTCACTTAGATAACGAAGAGATGGACTTTAGATATGCTTACGGTGTATGATGAGCG, or V5: CTTCCAGCCAGACCTCACCTTTAGATAACAGAGATGATGAGCG, or V5: CTTCCAGCCCAGACCTCACCTCTTTAGATAACAGAGATATGAGGAGCG, or V5: Based on a Cell-SELEX (systematic evolution of ligands by exponential enrichment) technology, two nucleic acid aptamers which can be combined with paclitaxel-resistant esophageal squamous cell carcinoma living cells in a high-specificity and high-affinity manner are obtained through screening, and the fact that the nucleic acid aptamers are combined with specific expression proteins on the surface of paclitaxel-resistant esophageal squamous cell carcinoma is preliminarily proved, so that the nucleic acid aptamers can be used for preparing the paclitaxel-resistant esophageal squamous cell carcinoma. Based on the application and further deep development of the related molecular probe, a certain technical basis can be provided for reversing the drug resistance of paclitaxel-resistant esophageal squamous carcinoma and improving the treatment effect of esophageal cancer, and a new technical thought and reference are provided for diagnosis and treatment of other similar diseases.
Owner:ZHENGZHOU UNIV

Medical compounds

The present invention provides a medicinal compound comprising a synthetic flavonoid derivative according to formula (I), which has a group at the C-3 position: wherein at least two of R2-R6 are H, and the rest are independently selected from: H, OH, R1, OR1, NO2, NH2, NHR1, F, Cl, Br, I; wherein R1 is a free radical. The present invention also provides dimerization, trimerization and tetramerization compounds, wherein two or more quercetin units are connected to a central linker (skeleton) via position 3 and a spacer. The medicinal compound can be used to treat malignant tumors, in particular malignant epithelial tumors, such as colon cancer, melanoma and / or squamous cell carcinoma of the skin, lung cancer, breast cancer, basal cell carcinoma (basal cell tumor). #imgabs0#
Owner:VERA SALUS RICERCA SRL

Application of LAMP1 inhibitor in preparation of medicine for preventing and / or treating esophageal cancer

PendingCN121221621AOrganic active ingredientsDigestive systemMetastatic esophageal cancerOncology
The invention discloses an application of an LAMP1 inhibitor in preparation of a medicine for preventing and / or treating esophageal cancer. Specifically, the application value of the LAMP1 inhibitor Parishin C in esophageal cancer treatment is found and verified for the first time, invasion and metastasis of esophageal squamous carcinoma cells and in-vivo lymph node metastasis can be remarkably inhibited by targeting LAMP1 protein and downstream signal channels of the LAMP1 protein and Parishin C, and a new drug choice is provided for metastatic esophageal cancer lacking effective treatment means clinically.
Owner:SHANGHAI CHEST HOSPITAL

Radix sophorae tonkinensis polysaccharide STGP-1, preparation method thereof and pharmaceutical use for treating lung squamous carcinoma

The application discloses radix sophorae tonkinensis polysaccharide STGP-1, a preparation method thereof and pharmaceutical use for treating lung squamous carcinoma, and relates to the technical field of medicines. The monosaccharide composition of STGP-1 includes fucose Fuc, arabinose Ara, galactose Gal, glucose Glc, xylose Xyl and mannose Man, and the molar ratio is 0.34:12.15:25.76:57.07:1.06:3.62. The STGP-1 is obtained by extraction, separation and purification from dried roots and rhizomes of radix sophorae tonkinensis, and the preparation method comprises the steps of pretreatment and crude extraction, impurity removal treatment, anion exchange column chromatography separation, gel column chromatography purification and the like. The STGP-1 can be used alone or in combination with anti-PD-1 monoclonal antibody for preparing a medicine for treating lung squamous carcinoma. The preparation process is stable, the source is natural, and the STGP-1 can provide a new high-efficiency and low-toxicity candidate medicine for immune combined treatment of lung squamous carcinoma.
Owner:GUANGXI MEDICAL UNIVERSITY

Lung squamous cell carcinoma organoid culture medium and culture method

The invention provides a lung squamous cell carcinoma organoid culture medium and a culture method. The lung squamous cell carcinoma organoid culture medium is prepared from the following components: R-spondin-1, Noggin, EGF (Epidermal Growth Factor), FGF10 (Fibroblast Growth Factor), FGF7 (Fibroblast Growth Factor), A83-01, Y-27632, Nicotinamide, Insulin, B27 Supplement, N-Acetylcysteine, Alpisib, GlutaMAX, primary cell antibiotics and the like. The lung squamous cell carcinoma organoid culture medium can be used for efficiently culturing lung squamous cell carcinoma tissues and successfully obtaining organoid, the formed organoid is highly similar to primary lung squamous cell carcinoma tissues in cell type, polarity and spatial hierarchical structure, and the micropathologic characteristics of tumors are truly reproduced. And the organoid can be stably passaged for a long time, so that an ideal and reliable preclinical model is provided for pathogenesis research, personalized drug screening and novel therapy development of lung squamous cell carcinoma.
Owner:BEIJING HOSPITAL

Methylation site marker for assisting early diagnosis of esophageal squamous cell carcinoma and application of methylation site marker

The invention relates to a methylation site marker for assisting in early diagnosis of esophageal squamous cell carcinoma and application of the methylation site marker, and belongs to the technical field of biomedicine. The methylation site marker is one or a combination of human peripheral blood mononuclear cell methylation sites cg05064044, cg03395511 and cg21548813, and the nucleotide sequence of the methylation site marker is as shown in SEQ ID NO. 1-3. According to the present invention, the methylation chip detection results show that the methylation levels of the cg05064044, the cg03395511 and the cg21548813 in the peripheral blood mononuclear cells of the esophageal squamous cell carcinoma patient are significantly increased compared to the health control group; the methylation levels of cg05064044, cg03395511 and cg21548813 sites in PBMC of esophageal squamous cell carcinoma patients in a training queue and a verification queue are all obviously higher than those of a healthy control group through further analysis. Finally, through ROC curve analysis, it is determined that the three methylation sites cg05064044, cg03395511 and cg21548813 have good specificity and sensitivity, have high diagnosis efficiency when being independently or jointly used for esophageal squamous cell carcinoma diagnosis and can be used as potential molecular markers for esophageal squamous cell carcinoma diagnosis.
Owner:SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY (SHANDONG PROVINCIAL HOSPITAL)

Marker LGALS9 for diagnosing nasopharyngeal squamous carcinoma and application thereof

The invention discloses a marker LGALS9 for diagnosing nasopharyngeal squamous carcinoma and application thereof, and belongs to the technical field of molecular diagnosis. The invention finds that the LGALS9 molecule has significant high expression in nasopharyngeal squamous cell carcinoma tissues, prompts that the LGALS9 can be used as a unique marker for diagnosing the nasopharyngeal squamous cell carcinoma, further constructs a diagnosis model by taking the LGALS9 as the marker, preferably detects the expression level of the marker LGALS9 in the cancer tissues by adopting an immunohistochemical method, and unexpectedly finds that the LGALS9 molecule can be used for diagnosing the nasopharyngeal squamous cell carcinoma tissues. The diagnostic performance of the diagnostic model constructed according to an immunohistochemical detection result is superior to that of a model constructed by adopting a protein spectrum detection method. The marker LGALS9 and the diagnostic model provided by the invention provide technical support for tissue traceability of nasopharyngeal squamous carcinoma, and have great clinical transformation potential.
Owner:FUDAN UNIV SHANGHAI CANCER CENT

Esophageal squamous carcinoma noninvasive screening system based on multi-marker saliva microbiome

The invention discloses an esophageal squamous cell carcinoma noninvasive screening system based on a multi-marker saliva microbiome, and relates to the technical field of microorganisms and oncology, the key points of the technical scheme are as follows: the system comprises an input module, an analysis module and an output module, the input module inputs abundance change of specific flora of a saliva sample needing to be screened; the analysis module is used for analyzing the input saliva sample flora data; and the output module outputs the analysis result of the analysis module and judges whether the screened saliva sample owner belongs to the high-risk population of the esophageal squamous cell carcinoma patient. The abundance change of the specific flora of the saliva sample is obtained through metagenome sequencing or targeted PCR detection, and a microbial characteristic model is constructed to distinguish high-risk people. By means of the system, early-stage, non-invasive and high-acceptability screening of esophageal squamous carcinoma can be achieved.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI